Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of EP-100 Given Intravenously 3 Out of 4 Weeks in Subjects With Advanced Solid Tumours.

Next Previous
Trial Profile

A Phase 1, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of EP-100 Given Intravenously 3 Out of 4 Weeks in Subjects With Advanced Solid Tumours.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EP 100 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Esperance Pharmaceuticals

Most Recent Events

  • 04 Jun 2012 Results were presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) and in an Esperance Pharmaceuticals media release.
  • 03 Apr 2012 Results will be reported at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2012, according to an Esperance Pharmaceuticals media release.
  • 31 Mar 2012 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top